Overview {#S1}
========

The molecular mechanism underlying somatic hypermutation (SHM) of rearranged immunoglobulin (Ig) genes (V\[D\]J) has been controversial for some time. Although the process of DNA deamination has dominated discussion in recent years, insufficient attention has been paid to a mechanism based on reverse transcription. One reason therefore for writing this *Perspective* is to counter balance a widely held view in the Ig SHM field that all relevant studies on the molecular mechanism deal only with the "DNA Deamination Model" which ended in complete consensus over 10 years ago sometime between 2004 and 2007 \[Table [1](#T1){ref-type="table"} and Ref. ([@B1]) in particular\]. The other is a personal tribute, in this anniversary year, to the founder of modern immunology, Sir Macfarlane Burnet. It is now 60 years since the publication of the first iteration of "The Clonal Selection Theory of Acquired Immunity" ([@B2]), the foundation stone of modern immunology. It was fully expounded in his 1959 book ([@B3]) where the main idea was clonal antigenic selection from a pre-existing diverse antibody repertoire from which somatic mutations might emerge as "forbidden" anti-self clones. Joshua Lederberg then gave the concept sharp molecular focus ([@B4]) as did Melvin Cohn and colleagues ([@B5]--[@B7]). Alastair Cunningham's concept of "clonal variation around a theme" placed antigen-driven SHM firmly within the context of expanding B lymphocyte clones ([@B8]). Somatic mutation of Ig variable region genes has therefore been part and parcel of Burnet's clonal selection concept since its inception and is central to a rational understanding of immunological diversification, self-tolerance and the emergence of cancer. We now have a very good idea of the molecular mechanism of SHM. I have chosen to fit this scientific progress within 60 key publications since the late 1950s (Table [1](#T1){ref-type="table"}). The most plausible central molecular mechanism of Ig SHM, that fits with and explains all the evidence ([@B9]--[@B11]) is based on "Reverse Transcription" of the base-modified Ig pre-mRNA (Figure [1](#F1){ref-type="fig"}). That is, error-prone reverse transcription, by DNA Polymerase-η, of the Ig pre-mRNA template intermediate at rearranged V\[D\]J gene somatic loci. The Ig pre-mRNA encoding the V\[D\]J region is copied off the transcribed DNA strand carrying prior AID C-to-U deamination lesions (Uracils and Abasic sites), and it also accumulates ADAR-deaminase mediated RNA editing A-to-I modifications. This already base-modified pre-mRNA sequence is then copied back to the B lymphocyte genomic DNA and integrated at the rearranged V\[D\]J site (concurrent with antigen-mediated selection of Ig receptor bearing B lymphocytes, Centrocytes, in the Germinal Center). This is essentially the "Reverse Transcriptase Mechanism" which Jeff Pollard and I first published 30 years ago ([@B12]). The mechanistic steps, many logical, are clearly outlined in Figure [1](#F1){ref-type="fig"}, which shows that the characteristic A \>\> T and G \>\> C strand bias-generating mutagenic activity is firmly focused on the nascent RNA intermediate in the context of the Transcription Bubble ([@B9]--[@B11], [@B13], [@B14]). Recent publications should be consulted for further definitive ADAR A-to-I editing of both RNA and DNA moieties at RNA:DNA hybrids within Transcription Bubbles ([@B11], [@B14], [@B15]). Not only is it important to understand the correct molecular mechanism of SHM for cancer diagnosis and detection ([@B16], [@B17]) but also to the current efforts to better understand ([@B18], [@B19]) the origin of Ig diversity involving the mechanism of evolution of the sets germline V segments and the long IGHV and IGLV haplotypes in individual human beings ([@B20], [@B21]).

###### 

History of somatic hypermutation (SHM): developments relevant to the reverse transcriptase mechanism.

  Year         Author                                   Main development-discovery-concept                                                            Reference
  ------------ ---------------------------------------- --------------------------------------------------------------------------------------------- ------------------
  1957--1959   Burnet                                   Large repertoire of antibodies each lymphocyte produces one specific antibody                 ([@B2])
  1959         Lederberg                                Somatic mutation explicit in lymphocyte development and Ab diversity                          ([@B4])
  1962         Fleishman et al.                         Amino acid variation in N -terminal regions of V or antigen binding regions                   ([@B22])
  1966         Brenner and Milstein                     Model: V region specific nicking and error prone repair---"SHM"                               ([@B23])
  1967         Smithies                                 Somatic "Master-\> Slave" Gene Recombination model Ab diversity                               ([@B24])
  1967         Edeleman and Gally                       Somatic recombination between duplicated V genes model Ab diversity                           ([@B25])
  1968         Cohn                                     Molecular biology of expectation---rationale for SHM and response to unexpected               ([@B5])
  1970         Weigert et al.                           Somatic variability in Lambda light chain V region protein sequences                          ([@B6])
  1970         Wu and Kabat                             Hypervariable regions coincide with and define antigen contact regions                        ([@B26])
  1974         Cunningham                               The generation of antibody diversity after antigen                                            ([@B8])
  1974         Cohn                                     Somatic mutation explanation for Ab diversity clearly laid out                                ([@B7])
  1976         Tonegawa and Steinberg                   DNA V gene counting confirms somatic mutation at molecular level in V lambda                  ([@B27])
  1977         Tonegawa et al.                          DNA V gene counting confirms somatic mutation at molecular level in V lambda                  ([@B28])
  1981         Gearhart et al.                          SHM of the TEPC15 VH rearranged gene *in vivo*                                                ([@B29])
  1981         Bothwell et al.                          SHM to the VH186.2 VH rearranged gene *in vivo*                                               ([@B30])
  1981         Seising and Storb                        SHM of the MOPC167 VK rearranged gene *in vivo*                                               ([@B31])
  1982         Gearhart                                 SHM in Rearranged (VDJ) Variable Region Genes *In vivo*                                       ([@B32])
  1983         Gearhart and Bogenhagen                  Somatic mutations occur in the 5′ and 3′ non-coding regions around VDJ genes                  ([@B33])
  1985         Berek and Milstein                       Use of hybridoma technique to sample somatic V\[D\]J mutant generation *in vivo*              ([@B34])
  1986         Cumano and Rajewsky                      Further use hybridoma technique to sample somatic VDJ mutants *in vivo*                       ([@B35])
  1987         Steele and Pollard                       Model: the reverse transcriptase mechanism of SHM                                             ([@B12])
  1987         Golding et al.                           First hint of strand biases in SHM patterns viz. A \> G *versus* T \> C                       ([@B36])
  1990         Both et al.                              Defining the 5′ and 3′ boundaries of SHM at VDJ genes                                         ([@B37])
  1990         Lebecque and Gearhart                    Defining 5′ and 3′ boundaries of SHM at VDJ genes                                             ([@B38])
  1991--1996   Rogozin et al.                           Identification R[G]{.ul}YW/WR[C]{.ul}Y and W[A]{.ul} hotspots in SHM data                     ([@B39], [@B40])
  1992         Steele et al.                            Defining the asymmetrical 5′ to 3′ somatic mutation distribution around V\[D\]J genes         ([@B41])
  1993         Betz et al.                              Defining the mutational hot spots across mutated V\[D\]J transgenes genes                     ([@B42])
  1995         Yelamos et al.                           Any non-lg sequences parked between Promotor and J-C intron somatically mutates               ([@B43])
  1996         Peters and Storb                         Strong evidence that transcription of VDJ target regions allows somatic mutation              ([@B44])
  1995--1998   Blanden et al.                           The SHM signature is written into the germline V segment array                                ([@B18])
  1998         Milstein et al.                          Both DNA strands targeted for G:C and A:T mutations in SHM                                    ([@B45])
  1998         Fukita et al.                            Strong correlative evidence that transcription of VDJ allows somatic mutation                 ([@B46])
  1998         Rada et al.                              In MSH2-deficient mice mutations are G:C focused suggesting two stages SHM                    ([@B47])
  1999         Masutani et al.                          Discovery of DNA Polymerase -eta and Y family translesion polymerases                         ([@B48])
  2000         Muramatsu et al.                         AID discovered---required to intiate SHM and Ig Class Switch Recombination                    ([@B49])
  2001--2002   Rogozin et al.; Pavlov et al.            Error-prone DNA Polymerase eta SHM spectrum correlates with W[A]{.ul} hotspots                ([@B50], [@B51])
  2001         Zeng et al.                              DNA Polymerase eta is the A:T mutator in SHM in humans                                        ([@B52])
  2002--2004   Neuberger et al.                         Definitive evidence that AID is a direct DNA C-to-U deaminase of the APOBEC family            ([@B1])
  2003         Bransteitter et al.                      AID deaminates C \> U on ssDNA---targets displaced strand Transcription Bubble                ([@B53])
  2003         Chaudhuri et al.                         AID deaminates C \> U on ssDNA---targets displaced strand Transcription Bubble                ([@B54])
  2003         Dickerson et al.                         AID deaminates C \> U on ssDNA---targets displaced strand Transcription Bubble                ([@B55])
  2004         Chaudhuri et al.                         AID deaminates C \> U on ssDNA---targets displaced strand Transcription Bubble                ([@B56])
  2004         Shen and Storb                           AID targets both strands at Transcription Bubbles during transcription VDJ                    ([@B57])
  2004         Rada et al.                              MSH2-MSH6 -/-and Uracil DNA Glycosylase -/-define G:C and A:T mutation phases                 ([@B58])
  2004         Franklin et al.                          Human DNA Polymerase eta is an efficient reverse transcriptase, as are kapp, iota             ([@B59])
  2004         Steele et al.                            First hint that A \> G versus T \> C strand bias involves an A \> l RNA edited intermediate   ([@B60])
  2005         Wilson et al.                            MSH2-MSH6 stimulates DNA polymerase eta, suggesting a role for A:T mutations                  ([@B61])
  2006         Steele et al                             Evidence WA \> WG mutations correlate with the number nascent WA RNA stem loops               ([@B62])
  2007         Delbos et al.                            Evidence that DNA Polymerase eta is the sole error-prone A:T SHM mutator *in vivo*            ([@B63])
  2009         Steele                                   SHM data 1984--2008 shows A»T, G»C strand biases explained by RNA/RT-model                    ([@B9])
  2010--2013   Steele and Lindley; Lindley and Steele   A\>\>T, G\>\>T SHM strand biases evident in non-lg genes across all cancer exomes             ([@B10], [@B13])
  2011         Basu et al.                              RNA exosome exposes ssDNA for AID on transcribed strand at Transcription Bubbles              ([@B64])
  2011         Maul et al.                              AID generated Uracils physically located in the DNA of VDJ & Ig class switch regions          ([@B65])
  2013         Lindley                                  Codon-context targeted somatic mutation in cancer exomes                                      ([@B16])
  2016         Steele                                   Extant evidence supports the RNA/RT-based model and not the DNA-based model                   ([@B11])
  2017         Zheng et al.                             ADAR can directly edit both RNA and DNA A-sites in RNA:DNA hybrids                            ([@B15])
  2017         Steele and Lindley                       ADAR A \> l Editing at RNA:DNA Hybrids is strong support for RNA/RT-based model               ([@B14])

![The reverse transcriptase mechanism of somatic hypermutation (SHM). Some elements of this figure have appeared before, and this figure *in toto* is a modified combination of parts from Figure 1 in Lindley and Steele ([@B10]), as well as from figures in Steele ([@B9], [@B11]) and Steele and Lindley ([@B14]). This is also an adaptation of the target site reverse transcription process of Luan et al. ([@B66]). Shown is an RNA Polymerase II-generated Transcription Bubble with C-site and A-site substrate deamination events by AID and ADAR proteins, which generates the strand-biased mutation signatures---A-to-G, G-to-A, G-to-T, and G-to-C ([@B9], [@B11], [@B14]). DNA strands shown by black lines; pre-mRNA as red lines; cDNA strands as thick blue lines due to DNA polymerase η ([@B59]). Green bars are Inosines. Shown also is the action of the RNA exosome ([@B64]) allowing access of AID deaminase to cytosines on the transcribed strand (TS). The ssDNA regions on the displaced non-transcribed strand (NTS) are established targets of AID action ([@B53]--[@B56]). Note that DNA mutations are first introduced as AID-mediated C-to-U, followed by excision of uracils by DNA glycosylase (UNG), which creates Abasic sites in the TS (these can mature into single strand nicks with 3′-OH ends via the action of AP endonuclease). These template Uracil and Abasic sites can be copied into pre-mRNA by RNA Pol II generating G-to-A and G-to-C modifications as shown ([@B67]). Following target site reverse transcription ([@B66]), this results in G-to-A and G-to-C mutations in the NTS, in a strand biased manner ([@B9]--[@B11], [@B14]). Separately at W[A]{.ul} targets in nascent dsRNA substrates, adenosine-to-inosine (A-to-I) RNA editing events, mediated by ADAR1 deaminase, are copied back into DNA by reverse transcription via Pol-η ([@B59]). In theory, ADARs can also deaminate the RNA and DNA moieties in the RNA: DNA hybrid ([@B14], [@B15]). The strand invasion and integration of newly synthesized cDNA TS, as well as random-template mismatch repair ([@B68]) are hypothesized additional steps (not shown here). In short, RNA Pol II introduces modifications in the Ig pre-mRNA as it copies TS DNA with AID lesions and this is coupled to A-to-I in dsRNA stem-loops near the transcription bubble ([@B62]) as well as in RNA:DNA hybrids within the bubble ([@B14], [@B15]). Next, a RT-priming substrate is formed when the nicked TS strand with an exposed 3′-OH end anneals with the base modified pre-mRNA copying template allowing cDNA synthesis by Y Family translesion DNA polymerase-η ([@B48]), now acting in its reverse transcriptase mode ([@B59]). These 3′-OH annealed priming sites could arise due to excisions at previous AID-mediated Abasic sites. Alternatively, they could arise due to an endonuclease excision associated with the MSH2-MSH6 heterodimer engaging a U:G mispaired lesion ([@B61]). Shown is an A-to-T transversion generated at the RT step at a template Inosine. ADAR, [A]{.ul}denosine [D]{.ul}eaminase that [a]{.ul}cts on [R]{.ul}NA; AP, an Abasic, or apurinic/apyrimidinic, site; APOBEC family, generic abbreviation for the dC-to-dU deaminase family of which AID is a member (e.g., APOBEC1; APOBEC3 A, B, C, D, F, G, H); AID, activation induced cytidine deaminase causing C-to-U lesions at WR[C]{.ul}Y/R[G]{.ul}YW C-site motifs in ssDNA; W, A, or U/T; W[A]{.ul}-site, target motif for ADAR deaminase including DNA polymerase-η error prone incorporation *in vitro* ([@B50], [@B51]); Y, pyrimidines T/U or C.; R, purine A or G.](fimmu-08-01611-g001){#F1}

Critical Focus on the RNA/RT-Mechanism {#S2}
======================================

The author has comprehensively reviewed the detailed evidence for the reverse transcription-based mechanism of SHM in previous and current studies ([@B9]--[@B11]). However, as flagged at the start of this article, many immunology researchers describe the mechanism of Ig SHM as being via DNA Polymerase-η-mediated DNA lesion repair independent of pre-mRNA in the context of the AID-initiated "DNA Deamination Model." It will be informative then to not only refer to these literatures but also summarize the evidence directly supporting an Ig pre-mRNA intermediate and reverse transcription, as summarized in Figure [1](#F1){ref-type="fig"}.

The alternative to the RNA/RT-based mechanism is the "DNA Deamination Model," which is assumed to be coupled to direct DNA-based error-prone repair via translesion DNA polymerase-η acting solely by error-prone copying of DNA templates ([@B50], [@B51]) during gap-repair surrounding AID-generated lesions (Uracils, Abasic sites, ssDNA nicks), as outlined in detail by Neuberger and associates ([@B1], [@B58]), Gearhart and associates ([@B61], [@B65]), and many other laboratories ([@B53]--[@B57], [@B63]) published mainly in the period 2002--2011. Quite apart from all the data at odds or inconsistent with this alternative theory, there have been three direct published tests of the Reverse Transcriptase Mechanism since 2001, one study was inconclusive and two studies reported positive data directly consistent with the RNA/RT-based mechanism.

In the first direct test of the RT model, Sack et al. ([@B69]) treated immunized mice with retroviral RT inhibitors, AZT, ddC and determined mutation frequencies in the anti-NP response of the rearranged V~H~186.2 sequence from control and test mice and showed a systematic lowering of the somatic mutation frequency by about 33--35% in both test groups compared to the control \[see Table 2 in Ref. ([@B69])\]. The authors however concluded that these retroviral RT inhibitors had no statistically significant effect (the *P* values were *P* = 0.056 and *P* = 0.069, respectively), thus claiming that "standard reverse transcription is not required for antibody V region hypermutation in the mouse" ([@B69]). This study and the conclusions drawn have been critically evaluated, and the present author considers that the data published in Sack et al. ([@B69]) have been misinterpreted ([@B9], [@B11], [@B70]).

In the next test, Franklin et al. \[([@B59]), Figure [1](#F1){ref-type="fig"} and legend\] showed that the sole known error-prone DNA polymerase involved in Ig SHM, DNA Polymerase-η ([@B52], [@B63]) is a very efficient reverse transcriptase: as indeed are human DNA Polymerases iota (-ι) and kappa (-κ) although less active than eta (-η).

Lastly Steele et al. ([@B62]) tested directly if a quantitative relationship exists between the number of appropriate Ig VκOxJκ5 mRNA secondary structures bearing W[A]{.ul} target sites for the ADAR1 RNA editor (adenosine to inosine, A-to-I) and the recorded incidence, across the full length of the *in vivo* mutated VκOx1Jκ5 sequence, of A-to-G mutations (the standard proxy for A-to-I RNA editing, where W = A or T). We showed that a highly *significant* and *specific* correlation (*P* \< 0.002) existed between the frequency (or number) of WA-to-WG mutations and the number of mRNA hairpins that could potentially form at such WA mutation sites. This is still the best direct data-driven evidence for an RNA intermediary in Ig SHM as it implies a direct role for both RNA editing and reverse transcription during SHM *in vivo*, occurring at the highest frequency in the nascent RNA stem-loops presenting WA-sites in dsRNA substrates just emergent from the Transcription Bubble. We now also know that *both* the RNA and DNA moieties in the RNA:DNA hybrid in the Transcription Bubble can potentially be A-to-I edited and contribute to A-to-G and T-to-C somatic mutations ([@B14], [@B15]).

These two sets of positive results consistent with the RNA/RT-based model are completely outside the ambit of the "DNA Deamination Model" neither explained by it nor predicted by it ([@B9], [@B11]). This fact was pointed out explicitly in 2008 ([@B71]).

The reader is referred to the considerable detail reviewed in Steele ([@B9], [@B11]) and Lindley and Steele ([@B10]), but attention should also be drawn to an awkward fact that cannot be explained by the "DNA Deamination" model yet is readily explained and predicted by the RNA/RT-mechanism (Figure [1](#F1){ref-type="fig"})---these are the clear strand biases of somatic mutations whereby mutations off A exceed mutations off T (A \>\> T, mainly A-to-G \>\> T-to-C) and yet paradoxically in the same data set or experiment, somatic mutations off G exceed mutations of C (G \>\> C, mainly G-to-A \>\> C-to-T). We have illustrated the contradictions of this paradox clearly in Lindley and Steele ([@B10])---as these characteristic strand biases are noted not only in Ig SHM datasets but also in AID/APOBEC driven "Ig-SHM-like responses" in cancer genomes ([@B10], [@B16]).

The other foundation inspiration for our work is the series of discoveries, begun in the 1950s ([@B72], [@B73]), which led to the demonstration in 1970 of reverse transcription in RNA tumor viruses by Howard Temin and David Baltimore ([@B74], [@B75]).

In summary, the DNA-based model of Neuberger and Gearhart, or the "DNA Deamination Model," is based on AID-induced C-to-U lesions and short-patch error-prone DNA repair by DNA Polymerase-η operating around such lesions ([@B1], [@B61], [@B65]). However, the RNA/RT-based mechanism ("Reverse Transcriptase Model") actually subsumes this initiating AID-mediated step and then couples it in the production of the full spectrum of strand-biased mutations at both G:C and A:T base pairs: error-prone cDNA synthesis via an RNA-dependent DNA polymerase (Pol-η) copying the base-modified Ig pre-mRNA template and leading to this now error-filled cDNA copy being integrated back into the normal chromosomal site (Figure [1](#F1){ref-type="fig"}). The modern form of this mechanism thus depends both on initiating AID C-to-U lesions in DNA and then long-tract error-prone cDNA synthesis of the TS by DNA Polymerase-η acting in its reverse transcriptase mode ([@B59]). There are several possible tests. The first could involve measuring the outcome of ADAR A-to-I editing of the RNA and DNA moieties at RNA:DNA hybrids ([@B15]) during SHM *in vivo*. Thus on a DNA polymerase-η deficient background ([@B52], [@B63]) the lowered number of mutations at A:T base pairs may allow A-to-I editing of the RNA:DNA hybrid and nascent dsRNA stem loops (Figure [1](#F1){ref-type="fig"}), but the lack of a RNA-to-DNA copying step could show that T-to-C mutations now balance or exceed A-to-G mutations. Furthermore, a direct test of ADAR deamination in Ig SHM *in vivo* could be achieved in either ADAR1 deficient Aicardi-Goutières Syndrome (AGS) patients ([@B76], [@B77]) or catalytically inactive ADAR1 mouse strains, such as Adar1^E861A/E861A^ Ifih1^−/−^ ([@B78]). The caveat to both approaches is a statistically sufficient numbers of A/T mutations and a strategy to avoid or minimize strand bias blunting PCR recombinant artifacts ([@B9]).
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